华润双鹤(600062.SH)子公司DC6001片获得FDA药物临床试验默示许可

智通财经01-12

智通财经APP讯，华润双鹤(600062.SH)发布公告，公司全资子公司北京双鹤润创科技有限公司(简称“双鹤润创”)就DC6001片向FDA(即“美国食品药品监督管理局”)提交的新药临床试验申请(简称“IND”)生效，该药品已进入可推进临床试验的阶段。DC6001片处于临床研发早期阶段，有待临床试验确证安全性、疗效和质量可控性，存在客观失败率等风险。根据美国药品注册相关的法律法规要求，该药品尚需在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2602137905?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-12 18:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602137905","market":"sh","top_or_hot":-1,"title":"华润双鹤(600062.SH)子公司DC6001片获得FDA药物临床试验默示许可","media":"智通财经","content":"<div>\n<p>智通财经APP讯，华润双鹤(600062.SH)发布公告，公司全资子公司北京双鹤润创科技有限公司(简称“双鹤润创”)就DC6001片向FDA(即“美国食品药品监督管理局”)提交的新药临床试验申请(简称“IND”)生效，该药品已进入可推进临床试验的阶段。DC6001片处于临床研发早期阶段，有待临床试验确证安全性、疗效和质量可控性，存在客观失败率等风险。根据美国药品注册相关的法律法规要求，该药品尚需在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1391705.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华润双鹤(600062.SH)子公司DC6001片获得FDA药物临床试验默示许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华润双鹤(600062.SH)子公司DC6001片获得FDA药物临床试验默示许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-12 18:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1391705.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，华润双鹤(600062.SH)发布公告，公司全资子公司北京双鹤润创科技有限公司(简称“双鹤润创”)就DC6001片向FDA(即“美国食品药品监督管理局”)提交的新药临床试验申请(简称“IND”)生效，该药品已进入可推进临床试验的阶段。DC6001片处于临床研发早期阶段，有待临床试验确证安全性、疗效和质量可控性，存在客观失败率等风险。根据美国药品注册相关的法律法规要求，该药品尚需在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1391705.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1391705.html","article_id":"2602137905","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602137905","pubTimestamp":1768212316,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，公司全资子公司北京双鹤润创科技有限公司(简称“双鹤润创”)就DC6001片向FDA(即“美国食品药品监督管理局”)提交的新药临床试验申请(简称“IND”)生效，该药品已进入可推进临床试验的阶段。DC6001片处于临床研发早期阶段，有待临床试验确证安全性、疗效和质量可控性，存在客观失败率等风险。根据美国药品注册相关的法律法规要求，该药品尚需在美国开展一系列临床研究并经美国药品审评部门审批通过后，方可上市。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600062":"华润双鹤","BK0175":"白马股","BK0010":"央企","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"China Resources Shuanghe (600062. SH) subsidiary DC6001 tablets obtained FDA drug clinical trial implied approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":1.5},"content_text":"智通财经APP讯，华润双鹤(600062.SH)发布公告，公司全资子公司北京双鹤润创科技有限公司(简称“双鹤润创”)就DC6001片向FDA(即“美国食品药品监督管理局”)提交的新药临床试验申请(简称“IND”)生效，该药品已进入可推进临床试验的阶段。DC6001片处于临床研发早期阶段，有待临床试验确证安全性、疗效和质量可控性，存在客观失败率等风险。根据美国药品注册相关的法律法规要求，该药品尚需在美国开展一系列临床研究并经美国药品审评部门审批通过后，方可上市。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602137905","isCrawlerRequest":true}